| 1 |
李雪莲，王雪梅. 高原性肺动脉高压监测手段研究进展 [J]. 分子影像学杂志，2018, 41(4): 538-541.
|
| 2 |
叶祥琳，古丽胡玛，岳 娇，等. 高原肺动脉高压的发病机制与药物治疗研究进展 [J]. 暨南大学学报(自然科学与医学版), 2022, 43(5): 467-479.
|
| 3 |
张 欢，华 毛，冯喜英，等. 脑钠肽、低氧诱导因子-1α、心肌型脂肪酸结合蛋白在高原肺动脉高压中的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2017, 10(5): 604-607.
|
| 4 |
Fisher Micah R, Forfia Paul R, Chamera Elzbieta, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension [J]. Am J Respir Crit Care Med, 2009, 179(7): 615-621.
|
| 5 |
León-Velarde Fabiola, Maggiorini Marco, Reeves John T, et al. Consensus statement on chronic and subacute high altitude diseases[J]. High Alt Med Biol, 2005, 6(2): 147-157.
|
| 6 |
梁 贞. 西藏不同海拔各慢性高原病的患病率调查与研究[D]. 西藏大学，2021: 34-65.
|
| 7 |
Brito Julio, Siques Patricia, Pena Eduardo. Long-term chronic intermittent hypoxia: a particular form of chronic high-altitude pulmonary hypertension [J]. Pulm Circ, 2020, 10(1 Suppl): 5-12.
|
| 8 |
Erzurum SC, Ghosh S, Janocha AJ, et al. Higher blood flow and circulating NO products offset high-altitude hypoxia among Tibetans [J]. Proc Natl Acad Sci U S A, 2007, 104(45): 17593-17598.
|
| 9 |
Pena Eduardo, Alam Samia El, Siques Patricia, et al. Oxidative stress and diseases associated with high-altitude exposure [J]. Antioxidants (Basel), 2022, 11(2): 267.
|
| 10 |
Negi Prakash Chand, Marwaha Rajeev, Asotra Sanjeev, et al. Prevalence of high altitude pulmonary hypertension among the natives of Spiti Valley-a high altitude region in Himachal Pradesh, India[J]. High Alt Med Biol, 2014, 15(4): 504-510.
|
| 11 |
Nicolas A, Ulloa, Jessica Cook. Altitude-induced pulmonary hypertension[M]. StatPearls. Treasure Island (FL); StatPearls Publishing, 2023: 117-245.
|
| 12 |
de Jesus Perez Vinicio A. High-altitude pulmonary vascular diseases [J]. Adv Pulm Hypertens, 2017, 15(3): 149-157.
|
| 13 |
Wang Liming, Yin Jun, Nickles Hannah T, et al. Hypoxic pulmonary vasoconstriction requires connexin 40-mediated endothelial signal conduction [J]. J Clin Invest, 2012, 122(11): 4218-4230.
|
| 14 |
Sydykov Akylbek, Mamazhakypov Argen, Maripov Abdirashit, et al. Pulmonary hypertension in acute and chronic high altitude maladaptation disorders [J]. Int J Environ Res Public Health, 2021, 18(4)：1692.
|
| 15 |
Swenson ER. Hypoxic pulmonary vasoconstriction[J]. High Alt Med Biol, 2013, 14(2): 101-110.
|
| 16 |
Pugliese Steven C, Poth Jens M, Fini Mehdi A, et al. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes[J]. Am J Physiol Lung Cell Mol Physiol, 2015, 308(3): L229-L252.
|
| 17 |
Tuder RM. Pulmonary vascular remodeling in pulmonary hypertension[J]. Cell Tissue Res, 2017, 367(3): 643-649.
|
| 18 |
Ryanto Gusty Rizky Teguh, Suraya Ratoe, Nagano Tatsuya. Mitochondrial dysfunction in pulmonary hypertension[J]. Antioxidants (Basel), 2023, 12(2): 372.
|
| 19 |
Marshall JD, Bazan I, Zhang Y, et al. Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both[J]. Am J Physiol Lung Cell Mol Physiol, 2018, 314(5): L782-L796.
|
| 20 |
Pullamsetti Soni Savai, Mamazhakypov Argen, Weissmann Norbert, et al. Hypoxia-inducible factor signaling in pulmonary hypertension [J]. J Clin Invest, 2020, 130(11): 5638-5651.
|
| 21 |
Huang X, Akgün EE, Mehmood K, et al. Mechanism of hypoxia-mediated smooth muscle cell proliferation leading to vascular remodeling[J]. Biomed Res Int, 2022, 2022: 3959845.
|
| 22 |
Ye Y, Xu Q, Wuren T. Inflammation and immunity in the pathogenesis of hypoxic pulmonary hypertension[J]. Front Immunol, 2023, 14: 1162556.
|
| 23 |
Palazon A, Goldrath AW, Nizet V, et al. HIF transcription factors, inflammation, and immunity [J]. Immunity, 2014, 41(4): 518-528.
|
| 24 |
Prabhakar Nanduri R, Semenza Gregg L. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2 [J]. Physiol Rev, 2012, 92(3): 967-1003.
|
| 25 |
Voelkel NF, Mizuno S, Bogaard HJ. The role of hypoxia in pulmonary vascular diseases: a perspective[J]. Am J Physiol Lung Cell Mol Physiol, 2013, 304(7): L457-L465.
|
| 26 |
Pu X, Lin X, Duan X, et al. Oxidative and endoplasmic reticulum stress responses to chronic high-altitude exposure during the development of high-altitude pulmonary hypertension[J]. High Alt Med Biol, 2020, 21(4): 378-387.
|
| 27 |
Dosek A, Ohno H, Acs Z, et al. High altitude and oxidative stress[J]. Respir Physiol Neurobiol, 2007, 158(2-3): 128-131.
|
| 28 |
Chai T, Qiu C, Xian Z, et al. A narrative review of research advances in hypoxic pulmonary hypertension[J]. Ann Transl Med, 2022, 10(4): 230.
|
| 29 |
Prieto-Lloret Jesus, Snetkov Vladimir A, Shaifta Yasin, et al. Role of reactive oxygen species and sulfide-quinone oxoreductase in hydrogen sulfide-induced contraction of rat pulmonary arteries[J]. Am J Physiol Lung Cell Mol Physiol, 2018, 314(4): L670-L685.
|
| 30 |
Sies H. Strategies of antioxidant defense[J]. Eur J Biochem, 1993, 215(2): 213-219.
|
| 31 |
Oyewole Anne O, Birch-Machin Mark A. Mitochondria-targeted antioxidants[J]. Faseb J, 2015, 29(12): 4766-4771.
|
| 32 |
He Y, Fang X, Shi J, et al. Apigenin attenuates pulmonary hypertension by inducing mitochondria-dependent apoptosis of PASMCs via inhibiting the hypoxia inducible factor 1α-KV1.5 channel pathway[J]. Chem Biol Interact, 2020, 317: 108942.
|
| 33 |
Guo L, Qiu Z, Wei L, et al. The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α1C [J]. Hypertension, 2012, 59(5): 1006-1013.
|
| 34 |
Brutsaert T. Why are high altitude natives so strong at high altitude? Nature vs. Nurture: Genetic Factors vs. Growth and Development [J]. Adv Exp Med Biol, 2016, 903: 101-112.
|
| 35 |
Chappell MA, Snyder LR Biochemical and physiological correlates of deer mouse alpha-chain hemoglobin polymorphisms [J]. Proc Natl Acad Sci U S A, 1984, 81(17): 5484-5488.
|
| 36 |
Tate Kevin B, Wearing Oliver H, Ivy Catherine M, et al. Coordinated changes across the O(2) transport pathway underlie adaptive increases in thermogenic capacity in high-altitude deer mice[J]. Proc Biol Sci, 2020, 287(1927): 20192750.
|
| 37 |
Evans Jonathan DW, Girerd Barbara, Montani David, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis [J]. Lancet Respir Med, 2016, 4(2): 129-137.
|
| 38 |
Machado Rajiv D, Southgate Laura, Eichstaedt Christina A, et al. Pulmonary arterial hypertension: A current perspective on established and emerging molecular genetic defects [J]. Hum Mutat, 2015, 36(12): 1113-1127.
|
| 39 |
Liu D, Liu Q-Q, Eyries M, et al. Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients [J]. Eur Respir J, 2012, 39(3): 597-603.
|
| 40 |
Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-Ⅱ，a receptor member of the TGF-beta family [J]. J Med Genet, 2000, 37(10): 741-745.
|
| 41 |
Petousi Nayia, Croft Quentin P P, Cavalleri Gianpiero L, et al. Tibetans living at sea level have a hyporesponsive hypoxia-inducible factor system and blunted physiological responses to hypoxia[J]. J Appl Physiol (1985), 2014, 116(7): 893-904.
|
| 42 |
Mishra Aastha, Mohammad Ghulam, Thinlas Tashi, et al. EGLN1 variants influence expression and SaO2 levels to associate with high-altitude pulmonary oedema and adaptation [J]. Clin Sci (Lond), 2013, 124(7): 479-489.
|
| 43 |
Beall Cynthia M, Cavalleri Gianpiero L, Deng Libin, et al. Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders [J]. Proc Natl Acad Sci U S A, 2010, 107(25): 11459-11464.
|
| 44 |
Aldashev Almaz A, Sarybaev Akpay S, Sydykov Akyl S, et al. Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype[J]. Am J Respir Crit Care Med, 2002, 166(10): 1396-1402.
|
| 45 |
Morrell NW, Sarybaev AS, Alikhan A, et al. ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders [J]. Lancet, 1999, 353(9155): 814.
|
| 46 |
Mirrakhimov Aibek E, Strohl Kingman P. High-altitude pulmonary hypertension: an update on disease pathogenesis and management [J]. Open Cardiovasc Med J, 2016, 10: 19-27.
|
| 47 |
León-Velarde Fabiola, Mejía Olga. Gene expression in chronic high altitude diseases [J]. High Alt Med Biol, 2008, 9(2): 130-139.
|
| 48 |
Lyu Qiang, Bai Yungang, Cheng Jiuhua, et al. Intermittent short-duration reoxygenation protects against simulated high altitude-induced pulmonary hypertension in rats[J]. Faseb J, 2021, 35(2): e21212.
|
| 49 |
蔡婷婷，达娃次仁. 慢性高原缺氧性肺动脉高压治疗进展[J]. 高原医学杂志，2018, 28(4): 61-64.
|
| 50 |
Thenappan Thenappan, Ormiston Mark L, Ryan John J, et al. Pulmonary arterial hypertension: pathogenesis and clinical management[J]. BMJ, 2018, 360: j5492.
|
| 51 |
Pham I, Wuerzner G, Richalet J-P, et al. Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans[J]. Eur J Clin Invest, 2010, 40(3): 195-202.
|
| 52 |
Kojonazarov Baktybek, Isakova Jainagul, Imanov Bakytbek, et al. Bosentan reduces pulmonary artery pressure in high altitude residents[J]. High Alt Med Biol, 2012, 13(3): 217-223.
|
| 53 |
王佳兴，张玉顺，刘海莲，等. 波生坦对高原性肺水肿的治疗作用[J]. 现代生物医学进展，2009, 9(4): 693-695.
|
| 54 |
方灵芝，邱学佳，关丽叶. 肺动脉高压治疗药物5型磷酸二酯酶抑制剂的Mini卫生技术评估[J]. 临床药物治疗杂志，2022, 20(5): 57-62.
|
| 55 |
赵保国，张秉丽. 高原肺动脉高压患者早期药物治疗临床研究[J]. 青海医药杂志，2020, 50(2): 6-8.
|
| 56 |
Ghofrani Hossein A, Reichenberger Frank, Kohstall Markus G, et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial [J]. Ann Intern Med, 2004, 141(3): 169-177.
|
| 57 |
XU Y, LIU Y, LIU J, et al. Meta-analysis of clinical efficacy of sildenafil, a phosphodiesterase type-5 inhibitor on high altitude hypoxia and its complications[J]. High Alt Med Biol, 2014, 15(1): 46-51.
|
| 58 |
Richalet JP, Gratadour P, Robach P, et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension[J]. Am J Respir Crit Care Med, 2005, 171(3): 275-281.
|
| 59 |
Clapp JR, Watson JF, Berliner RW. Effect of carbonic anhydrase inhibition on proximal tublar bicarbonate reabsorption[J]. Am J Physiol, 1963, 205: 693-696.
|
| 60 |
Swenson ER. Carbonic anhydrase inhibitors and ventilation: a complex interplay of stimulation and suppression[J]. Eur Respir J, 1998, 12(6): 1242-1247.
|
| 61 |
Bärtsch Peter, Swenson Erik R. Acute high-altitude illnesses[J]. N Engl J Med, 2013, 369(17): 1666-1667.
|
| 62 |
Richalet Jean-Paul, Rivera Maria, Bouchet Patrick, et al. Acetazolamide：a treatment for chronic mountain sickness[J]. Am J Respir Crit Care Med, 2005, 172(11): 1427-1433.
|
| 63 |
Spyropoulos Fotios, Michael Zoe, Finander Benjamin, et al. Acetazolamide Improves Right Ventricular Function and Metabolic Gene Dysregulation in Experimental Pulmonary Arterial Hypertension[J]. Front Cardiovasc Med, 2021, 8: 662870.
|
| 64 |
Lichtblau Mona, Berlier Charlotte, Saxer Stéphanie, et al. Acute Hemodynamic Effect of Acetazolamide in Patients With Pulmonary Hypertension Whilst Breathing Normoxic and Hypoxic Gas: A Randomized Cross-Over Trial[J]. Front Med (Lausanne), 2021, 8: 681473.
|
| 65 |
Pietta PG. Flavonoids as antioxidants [J]. J Nat Prod, 2000, 63(7): 1035-1042.
|
| 66 |
Veith C, Drent M, Bast A, et al. The disturbed redox-balance in pulmonary fibrosis is modulated by the plant flavonoid quercetin [J]. Toxicol Appl Pharmacol, 2017, 336: 40-48.
|
| 67 |
Xiao X, Shi D, Liu L, et al. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling [J]. PLoS One, 2011, 6(8): e22934.
|
| 68 |
Yao Y, Feng Y, Lin W. Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angina pectoris [J]. Int J Cardiol, 2015, 182: 46-47.
|
| 69 |
Li Z, Guo J, Liu C, et al. Compound danshen dripping pill promotes adaptation to acute high-altitude exposure [J]. High Alt Med Biol, 2020, 21(3): 258-264.
|
| 70 |
Hu Y, Sun J, Wang T, et al. Compound Danshen Dripping Pill inhibits high altitude-induced hypoxic damage by suppressing oxidative stress and inflammatory responses [J]. Pharm Biol, 2021, 59(1): 1585-1593.
|